Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Mangoceuticals, Inc. - SIC # 5940 -
Ticker
Exchange
SIC #
Website
Latest Ticker
MGRX
Nasdaq
5940
www.mangoceuticals.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Mangoceuticals, Inc.
Mangoceuticals Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 Studies and Engages Vipragen Biosciences to Structure H5N1 Cohort for Expanded Research
- Feb 6th, 2025 12:00 pm
Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation
- Feb 3rd, 2025 1:30 pm
Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent
- Dec 19th, 2024 10:33 pm
Mangoceuticals, Inc. Initiates Investigation into Potential Stock Manipulation Scheme Following Recent Reverse Stock Split
- Dec 4th, 2024 12:00 pm
Mangoceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
- Oct 31st, 2024 12:00 pm
MangoRx Announces Formation of Strategy and Alternatives Committee
- Oct 22nd, 2024 12:00 pm
MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly
- Oct 21st, 2024 9:10 pm
Mangoceuticals, Inc. Announces Participation at the Centurion One Capital 2nd Annual Bahamas Summit 2024
- Oct 18th, 2024 12:45 pm
Mangoceuticals announces 1-for-15 reverse stock split
- Oct 12th, 2024 9:20 pm
MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN
- Oct 11th, 2024 9:15 pm
MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions
- Oct 3rd, 2024 12:30 pm
MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment
- Oct 1st, 2024 11:30 am
Mangoceuticals Second Quarter 2024 Earnings: US$0.092 loss per share (vs US$0.14 loss in 2Q 2023)
- Aug 17th, 2024 1:19 pm
MangoRx Reports 1,685% Increase in Shareholders’ Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024
- Aug 15th, 2024 1:25 pm
MangoRx Receives Certificate of Grant in India for its Respiratory Illness and Preventive Care Technology Patent
- Aug 13th, 2024 8:00 pm
MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide
- Aug 9th, 2024 12:15 pm
MangoRx Receives Request for Proposal (RFP) From ISFLST for New Male Enhancement Product Exclusive for the Asian Market
- Aug 8th, 2024 12:30 pm
MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention Technology
- Jul 24th, 2024 12:15 pm
Mangoceuticals CEO Jacob Cohen Featured on Benzinga All-Access
- Jul 18th, 2024 8:05 pm
MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts
- Jul 16th, 2024 12:20 pm
Scroll